New York, NY -- (SBWIRE) -- 01/22/2018 -- The infection below the level of larynx is said to be lower respiratory tract infection. Many a times, lower respiratory tract infection is called pneumonia. These infection are not defined uniformly, but epidemiologically, these infections includes flu, bronchitis, bronchiolitis, and pneumonia. Many microorganisms can cause the infection such as virus viz. adenoviruses, coronaviruses, parainfluenza virus, rhinoviruses etc and bacteria viz. Bordetella pertussis, Chlamydophila pneumoniae and Mycoplasma pneumoniae etc. Lower respiratory tract infection are leading cause of morbidity and mortality in children and adults worldwide.

Request to Browse Full Table of Content, figure and Tables @ https://www.persistencemarketresearch.com/toc/14866

The global lower respiratory tract infection market is anticipated to witness lucrative growth due to increasing prevalence of lung diseases, surge in geriatric population, rise in risk of pneumonia in children, etc. According to World Health Organization (WHO), Respiratory syncytial virus (RSV) is responsible for 30 million lower respiratory tract infection cases in children worldwide, the prevalence of such viral diseases will drive the growth of the global market through 2027. Furthermore, the newer advances in treatment and the facilities, treatment with lower potential side effects, etc. will propel the growth of the global market during the forecast period. Inappropriate and lack of in-vitro facilities for conducting research studies for novel treatment alternatives is the factor that can hamper the growth of the global lower respiratory tract infection market during the forecast period.

Asia Pacific market is anticipated to be the fastest growing market due to factors such as rise in patient awareness, improved health care infrastructure and facilities, high disposable income, prevalence of unhealthy lifestyle etc.

Request Sample Report @ https://www.persistencemarketresearch.com/samples/14866

Major players operating in the global lower respiratory tract infection market include Sanofi Pasteur SA, AstraZeneca, Merck & Co., Inc., GlaxoSmithKline plc., Pfizer Inc. etc among others worldwide. To maintain a significant position in the global market, companies focus on strategies like mergers and acquisitions, treatment efficiency and efficacy, cost friendly services etc.